Zan Fleming

Zan Fleming is the current Director at Orgenesis. Prior to this, they served as the Chief Medical Officer and Chairman of the Board at Exsulin from January 2005 to December 2011. There, they were responsible for leading clinical development and regulatory strategy for INGAP Peptide and other islet regeneration therapies. Prior to their work at Exsulin, Zan Fleming was employed at Kinexum from January 1986 to December 1998 as a supervisory physician.

Dr. Zan Fleming received their M.D. from Emory University School of Medicine and completed a fellowship in endocrinology at Vanderbilt University School of Medicine. Zan is currently a fellow in metabolism at the National Institutes of Health.